Guizhou Sanli PharmaceuticalLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Guizhou Sanli PharmaceuticalLtd heeft een totaal eigen vermogen van CN¥1.9B en een totale schuld van CN¥577.7M, wat de schuld-eigenvermogensverhouding op 31.1% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥3.1B en CN¥1.2B. De EBIT Guizhou Sanli PharmaceuticalLtd is CN¥327.7M waardoor de rentedekking -7.5 is. Het heeft contanten en kortetermijnbeleggingen van CN¥593.1M.

Belangrijke informatie

31.1%

Verhouding schuld/eigen vermogen

CN¥577.72m

Schuld

Rente dekkingsratio	-7.5x
Contant	CN¥593.10m
Aandelen	CN¥1.86b
Totaal verplichtingen	CN¥1.20b
Totaal activa	CN¥3.06b

Recente financiële gezondheidsupdates

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25

Recent updates

We Ran A Stock Scan For Earnings Growth And Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Passed With Ease

Oct 16

Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Aug 25

Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Aug 03

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Apr 23

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 06

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥1.7B ) 603439 } overtreffen de korte termijn passiva ( CN¥845.7M ).

Langlopende schulden: De kortetermijnactiva 603439 ( CN¥1.7B ) overtreffen de langetermijnschulden ( CN¥355.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 603439 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 603439 is de afgelopen 5 jaar gestegen van 0% naar 31.1%.

Schuldendekking: De schuld van 603439 wordt goed gedekt door de operationele kasstroom ( 31.8% ).

Rentedekking: 603439 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Guizhou Sanli PharmaceuticalLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.14 in 3Q 2023)

We Ran A Stock Scan For Earnings Growth And Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Passed With Ease

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for 6,722,700 shares, representing 1.64% for CNY 120 million.

Hainan Yuexin Pharmaceutical Investment Partnership (General Partnership) acquired 5.12% stake in Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) from Zhang Hai for approximately CNY 220 million.

Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2023)

Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Now 22% undervalued after recent price drop

Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Now 20% undervalued after recent price drop

Guizhou Sanli Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 29, 2024

Guizhou Sanli Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 1Q 2023)

Now 20% overvalued

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 22% undervalued

Now 21% undervalued

Now 20% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.089 in 3Q 2022)

Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.089 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 2Q 2021)

GuiZhou SanLi Pharmaceutical Co.,Ltd (SHSE:603439) signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.06 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GuiZhou SanLi Pharmaceutical Co., Ltd. (SHSE:603439) agreed to acquire 95% stake in Guiyang Dechang Xiang Pharmaceutical Co., Ltd from Guizhou Jingyi Garden Ecological Planting Co., Ltd. and Guiyang Dechang Xiang Pharmaceutical Co., Ltd.’s Trade Union Committee for CNY 230 million.

Now 21% undervalued

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.005 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.053 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.24 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.39

New 90-day low: CN¥18.03

New 90-day low: CN¥20.70

Third quarter earnings released

New 90-day low: CN¥23.10

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low - CN¥26.68

First half earnings released

First half earnings released

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report First Half, 2020 Results on Aug 28, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven